Chen Yen-Fu Adam, Mocanu Bianca, Akidil Ezgi, Pich Dagmar, Mautner Josef, Sugden Bill, Hammerschmidt Wolfgang
EBV Vaccine Development, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany.
Partner site Munich, German Centre for Infection Research (DZIF), Munich, Germany.
J Virol. 2025 Jul 22;99(7):e0062625. doi: 10.1128/jvi.00626-25. Epub 2025 May 30.
Epstein-Barr virus (EBV) is usually maintained latently on passaging in cell culture, as are most herpesviruses . Its fitness, or its ability to infect and replicate in naïve cells, cannot be ascertained by serially passaging it in host cells because no identified cell line initially supports a productive infection by it. Yet its fitness is critical to EBV's remarkable success as a human pathogen. We have, therefore, developed multiple approaches to assess EBV's fitness upon being reactivated from its familiar state of latency. We established and tested expression plasmids for 77 viral genes and a set of shRNAs targeting 25 viral genes to measure how increasing and decreasing their levels affected the fitness of the released stocks of virus. Four of their properties were then analyzed: (i) their concentrations of physical particles, (ii) their binding to the CD21 receptor on a B-cell line, (iii) their entry into human primary B cells, and (iv) their infectious titers. These analyses identified multiple EBV genes whose altered levels of expression altered the biological activities of the released virus. These measurements revealed, though, an unexpected insight into the robustness of EBV produced from latently infected cells. EBV is amazingly resilient to any increased expression of its genes. The levels expressed in cells, as they support an induced productive infection, therefore are close to optimal for the fitness of the released virus.IMPORTANCEPopulations of viruses accumulate mutations while being propagated. While most mutations are neutral or disadvantageous, some confer on the variant a selective advantage, increasing its infectivity. These variants can be identified by serial passaging virus stocks, allowing those with increased fitness to predominate. This approach does not work for Epstein-Barr virus (EBV), for which no identified cell line initially supports its productive infection. How mutations accumulate in EBV as it is propagated latently to affect its fitness was unknown. We have devised an approach to assess EBV's fitness upon being reactivated. Our findings suggest that EBV during its many latent generations has maintained a strikingly robust productive fitness.
爱泼斯坦-巴尔病毒(EBV)在细胞培养传代过程中通常处于潜伏状态,大多数疱疹病毒也是如此。由于没有已确定的细胞系最初能支持其进行 productive 感染,所以无法通过在宿主细胞中连续传代来确定其适应性,即它在未感染细胞中感染和复制的能力。然而,其适应性对于EBV作为一种人类病原体的显著成功至关重要。因此,我们开发了多种方法来评估EBV从其熟悉的潜伏状态重新激活后的适应性。我们建立并测试了77个病毒基因的表达质粒和一组靶向25个病毒基因的短发夹RNA(shRNAs),以测量它们水平的增加和降低如何影响释放的病毒株的适应性。然后分析了它们的四个特性:(i)它们的物理颗粒浓度,(ii)它们与B细胞系上CD21受体的结合,(iii)它们进入人原代B细胞的情况,以及(iv)它们的感染滴度。这些分析确定了多个EBV基因,其表达水平的改变会改变释放病毒的生物学活性。不过,这些测量揭示了对潜伏感染细胞产生的EBV的稳健性的一个意想不到的见解。EBV对其基因的任何增加表达都具有惊人的弹性。因此,在支持诱导性 productive 感染的细胞中表达的水平对于释放病毒的适应性而言接近最佳。
病毒群体在繁殖过程中会积累突变。虽然大多数突变是中性的或不利的,但有些会赋予变体选择性优势,增加其感染性。这些变体可以通过连续传代病毒株来识别,使适应性增加的变体占主导地位。这种方法对爱泼斯坦-巴尔病毒(EBV)不起作用,因为没有已确定的细胞系最初能支持其 productive 感染。在EBV潜伏传播过程中突变如何积累以影响其适应性尚不清楚。我们设计了一种方法来评估EBV重新激活后的适应性。我们的研究结果表明,EBV在其许多潜伏代中一直保持着惊人的稳健 productive 适应性。